Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection-Reference-Cited by-同舟云学术

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Published:2021-02-05 Issue:6529 Volume:371 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Dan Jennifer M.¹²^ORCID,Mateus Jose¹^ORCID,Kato Yu¹^ORCID,Hastie Kathryn M.¹^ORCID,Yu Esther Dawen¹^ORCID,Faliti Caterina E.¹,Grifoni Alba¹^ORCID,Ramirez Sydney I.¹²^ORCID,Haupt Sonya¹^ORCID,Frazier April¹^ORCID,Nakao Catherine¹,Rayaprolu Vamseedhar¹^ORCID,Rawlings Stephen A.²^ORCID,Peters Bjoern¹³^ORCID,Krammer Florian⁴^ORCID,Simon Viviana⁴⁵⁶^ORCID,Saphire Erica Ollmann¹²^ORCID,Smith Davey M.²^ORCID,Weiskopf Daniela¹^ORCID,Sette Alessandro¹²^ORCID,Crotty Shane¹²^ORCID

Affiliation:

1. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.

2. Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.

3. Department of Medicine, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.

4. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

5. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

6. The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Abstract

Variable memory Immune memory against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps to determine protection against reinfection, disease risk, and vaccine efficacy. Using 188 human cases across the range of severity of COVID-19, Dan et al. analyzed cross-sectional data describing the dynamics of SARS-CoV-2 memory B cells, CD8 + T cells, and CD4 + T cells for more than 6 months after infection. The authors found a high degree of heterogeneity in the magnitude of adaptive immune responses that persisted into the immune memory phase to the virus. However, immune memory in three immunological compartments remained measurable in greater than 90% of subjects for more than 5 months after infection. Despite the heterogeneity of immune responses, these results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals. Science , this issue p. eabf4063

Funder

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Wellcome

Mastercard Incorporated

JPB Foundation

Open Philanthropy Project

Steven and Alexandra Cohen Foundation

John and Mary Tu Foundation

Publisher

American Association for the Advancement of Science (AAAS)